Multiple Sclerosis, Chronic Progressive
Showing 26 - 50 of >10,000
Progressive Multiple Sclerosis Trial in Lille, Strasbourg (Placebo, Masitinib (4.5))
Recruiting
- Progressive Multiple Sclerosis
- Placebo
- Masitinib (4.5)
-
Lille, France
- +1 more
Jul 1, 2022
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Los Angeles (Metformin 500 Mg Oral
Recruiting
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Placebo oral tablet identical to metformin, up to 4 tablets a day
-
Los Angeles, CaliforniaUniversity of California, Los Angeles
May 2, 2022
Progressive Multiple Sclerosis Trial in Berlin (GZ402668, Placebo, Acyclovir)
Completed
- Progressive Multiple Sclerosis
- GZ402668
- +2 more
-
Berlin, GermanyInvestigational Site Number 276001
Apr 22, 2022
Visual Processing Speed and Objective Analysis of Ocular
Enrolling by invitation
- Multiple Sclerosis
- +3 more
- Eye tracking
- +3 more
-
Valladolid, SpainIOBA - Universidad de Valladolid
Jan 20, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in San Francisco
Recruiting
- Multiple Sclerosis
- +2 more
- N-acetyl cysteine
- Placebo
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 22, 2022
Gray Matter Demyelination in Primary Progressive MS at 7T
Recruiting
- Primary Progressive Multiple Sclerosis
-
Hvidovre, DenmarkDanish Research Centre for Magnetic Resonance
Jun 5, 2022
Progressive Multiple Sclerosis, Fatigue Trial in San Francisco (N-acetyl cysteine, Placebo)
Completed
- Progressive Multiple Sclerosis
- Fatigue
- N-acetyl cysteine
- Placebo
-
San Francisco, CaliforniaUniversity of California San Francisco
Sep 6, 2022
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive Trial in Porto Alegre
Not yet recruiting
- Multiple Sclerosis, Chronic Progressive
- +3 more
- Nordic Walking (NWG)
- +2 more
-
Porto Alegre, Rio Grande Do Sul, BrazilUniversidade Federal do Rio Grande do Sul
May 17, 2022
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Salt Lake City
Recruiting
- Secondary Progressive Multiple Sclerosis
- +2 more
- Ferumoxytol infusion
- +2 more
-
Salt Lake City, UtahUniversity of Utah Health Imaging and Neurosciences Center
Jun 22, 2022
Secondary Progressive Multiple Sclerosis (SPMS) Trial in Tel Aviv (SCM-010)
Not yet recruiting
- Secondary Progressive Multiple Sclerosis (SPMS)
- SCM-010
-
Tel Aviv, IsraelTel Aviv Medical Center
Oct 26, 2022
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Marseille, Rennes (Magnetic
Recruiting
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Magnetic Resonance Imaging
- +3 more
-
Marseille, France
- +1 more
Jan 14, 2022
Upper Extremity Function in Multiple Sclerosis Advanced
Active, not recruiting
- Multiple Sclerosis
- +7 more
-
Tampa, FloridaCarol and Frank Morsani Center for Advanced Healthcare
Nov 2, 2022
Multiple Sclerosis, Progressive Multiple Sclerosis Trial in Norway (MSCs, Saline)
Recruiting
- Multiple Sclerosis
- Progressive Multiple Sclerosis
- MSCs
- Saline
-
Tromsø, Troms Og Finnmark, Norway
- +3 more
Jul 28, 2022
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial
Active, not recruiting
- Secondary Progressive Multiple Sclerosis
- +2 more
- ACTH
- Placebo
-
Minneapolis, Minnesota
- +2 more
Mar 29, 2022
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis Trial (Intranasal Foralumab
Withdrawn
- Primary Progressive Multiple Sclerosis
- +2 more
- Intranasal Foralumab Solution
- Placebo
- (no location specified)
Feb 14, 2022
Multiple Sclerosis, Secondary Progressive Trial in Calgary (Hydroxychloroquine Pill, Indapamide Pill)
Recruiting
- Multiple Sclerosis, Secondary Progressive
- Hydroxychloroquine Pill
- Indapamide Pill
-
Calgary, Alberta, CanadaFoothills Medical Centre
May 16, 2022
Measuring Active Microglia in Progressive Multiple Sclerosis
Completed
- Secondary Progressive Multiple Sclerosis
- [C11]PK-1195 PET scan
-
New York, New YorkWeill Cornell Medical College
Jan 14, 2022
Multiple Sclerosis Trial in Canada, United States (Lipoic acid, Placebo)
Active, not recruiting
- Multiple Sclerosis
- Lipoic acid
- Placebo
-
Birmingham, Alabama
- +10 more
Jan 31, 2023
Multiple Sclerosis, Primary Progressive Trial in Bordeaux, Limoges, Poitiers (Clinical assessment, Ecological evaluation,
Recruiting
- Multiple Sclerosis, Primary Progressive
- Clinical assessment
- +4 more
-
Bordeaux, France
- +2 more
Mar 31, 2022
Primary Progressive Multiple Sclerosis, Exercise, Cardiorespiratory Fitness Trial in Valens (HIIT, MCT)
Recruiting
- Primary Progressive Multiple Sclerosis
- +2 more
- HIIT
- MCT
-
Valens, Sankt Gallen, SwitzerlandKlinik Valens, Valens rehabilitation clinic
Jun 9, 2022
Primary Progressive Multiple Sclerosis Trial in Durham (DUOC-01)
Recruiting
- Primary Progressive Multiple Sclerosis
- DUOC-01
-
Durham, North CarolinaDuke University Medical Center
Jan 25, 2022
Progressive Multiple Sclerosis Trial in Indianapolis (G-EO System (Reha Technology AG: Olten, Switzerland), Conventional
Completed
- Progressive Multiple Sclerosis
- G-EO System (Reha Technology AG: Olten, Switzerland)
- Conventional Physical Therapy
-
Indianapolis, IndianaNeurorehabilitation and Robotics at IU Health Neuroscience Cente
Jan 20, 2022
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Caen (Cognitive rehabilitation,
Recruiting
- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Cognitive rehabilitation
- Standard Psychological care
-
Caen, Calvados, FranceUniversity Hospital of Caen
Mar 8, 2022
Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))
Active, not recruiting
- Secondary Progressive Multiple Sclerosis
- BAF312
- Baseline disease modifying therapies (DMTs)
-
Mittweida, Sachsen, Germany
- +9 more
Aug 9, 2022
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial
Recruiting
- Relapsing Remitting Multiple Sclerosis
- +2 more
- Ixazomib (NINLARO®) capsules / Matching placebo capsules
-
London, Greater London, United KingdomRoyal London Hospital, Barts Health NHS Foundation Trust
Feb 17, 2022